User profiles for J. Saraiva
 | jorge saraivaFood Technology, Biotechnology, and Biocatalysts, Aveiro University Verified email at ua.pt Cited by 14411 |
The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease)
…, IAAS Lima, JVA de Oliveira Nunes, JS Saraiva… - Psychiatry …, 2020 - Elsevier
… Carlos Kennedy Tavares Lima a , Poliana Moreira de Medeiros Carvalho a , Igor de Araújo
Araruna Silva Lima b , José Victor Alexandre de Oliveira Nunes b , Jeferson Steves Saraiva …
Araruna Silva Lima b , José Victor Alexandre de Oliveira Nunes b , Jeferson Steves Saraiva …
Current applications and new opportunities for the use of pulsed electric fields in food science and industry
Several studies have demonstrated the feasibility of pulsed electric fields (PEF) for different
applications in food industry. PEF technology is therefore a valuable tool that can improve …
applications in food industry. PEF technology is therefore a valuable tool that can improve …
Emerging opportunities for the effective valorization of wastes and by-products generated during olive oil production process: Non-conventional methods for the …
Background A large amount of wastes and by-products are generated during olive oil
production process. Traditionally, these products have been considered as a problem. However, …
production process. Traditionally, these products have been considered as a problem. However, …
[HTML][HTML] Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
…, B Merkely, E O'Meara, JFK Saraiva… - … England Journal of …, 2022 - Mass Medical Soc
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure and cardiovascular death among patients with chronic heart failure …
for heart failure and cardiovascular death among patients with chronic heart failure …
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
…, C Rodrigues, GR Velasco, JFK Saraiva… - The lancet Respiratory …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …
properties. This study evaluates the efficacy and safety of baricitinib in combination …
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Background Patients with peripheral artery disease have an increased risk of cardiovascular
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. …
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. …
[HTML][HTML] Tofacitinib in patients hospitalized with Covid-19 pneumonia
…, RH Furtado, LN Maia, JF Saraiva… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who
are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. Methods …
are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. Methods …
[HTML][HTML] Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …
…, MLB Piruzeli, JD Goldman, JFK Saraiva… - The Lancet …, 2022 - thelancet.com
Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …
Chemical composition and antibacterial and antioxidant properties of commercial essential oils
The aim of this work was to determine the effectiveness of 17 essential oils to inhibit the
growth of seven food-borne spoilage and pathogenic bacterial strains (Brochothrix …
growth of seven food-borne spoilage and pathogenic bacterial strains (Brochothrix …
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
…, JA ABRANTES, E MANENTI, G REIS, J Saraiva… - The Lancet, 2018 - thelancet.com
Background Coronary artery disease is a major cause of morbidity and mortality worldwide,
and is a consequence of acute thrombotic events involving activation of platelets and …
and is a consequence of acute thrombotic events involving activation of platelets and …